Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of drugs that are allowed to be compounded. In a Citizen Petition posted on ...

Victoza has just given Novo Nordisk a boost, with new data showing it can cut the risk of heart attacks, strokes and cardiovascular death in type 2 diabetes patients. The five-year LEADER study of ...

Against a backdrop of manufacturing prioritisation, Novo ... pen needles market. The needle device market is forecast to grow to over $6.8bn by 2033, according to analysis by GlobalData. Novo ...

Novo Nordisk also announced encouraging phase 3 data from its investigational drug semaglutide, which like Victoza is a GLP-1 class drug, but can be administered by injection weekly, not daily.

BURLINGAME, CA, UNITED STATES, January 14, 2025 /EINPresswire / -- The Pen Needles Market Report is the result of extensive research and analysis conducted by our team of experienced market ...